The Role of the Kidney in Glucose Homeostasis and Diabetes



Program Description

For many years the role of the kidney in glucose homeostasis through gluconeogenesis and glucose re-absorption, through SGLT2 in the tubules, has largely been lost on clinicians; as well as its importance in the development of diabetes. Recently new agents, which inhibit the function of the SGLT2, have been approved for the management of SGLT2. Proper understanding of the use of these new agents is largely missing. The overall objective of this CME program is to shed light on the role of the kidney in energy metabolism, and to provide expert insight on the physiology of SGLT2 in the development and the management of diabetes. The mechanism and potential role of the SGLT2-i in managing diabetes will be discussed.

Learning Objectives

Discuss the role of the Kidney in energy metabolism, and its contribution, through gluconeogenesis and glucose re-absorption via the sodium glucose-linked transporter 2, to glucose levels.
Analyze the relationship of glucose toxicity, beta cell dysfunction, and insulin resistance in T2DM & its potential association with SGLT2 inhibitors.
Describe the mechanism of SGLT2 inhibitors in reducing glucose re-absorption , and their role in the management of type 2 diabetes. 

Activity information

  • Duration: 2.5 hours you will earn 2.5 FREE AMA PRA Category 1 Credit(s)™

  • Based on Satellite Symposium held on November 20, 2014 in association with the 12th Annual World Congress on the Insulin Resistance, Diabetes & Cardiovascular Disease.

  • Date of release:  January 30th 2015

  • Date of expiration: January 30th, 2016

Target Audience

Endocrinologists, cardiologists, family physicians, internists, diabetologists, dieticians, nurse practitioners, and other health care professionals interested in diabetes and obesity.

Program Provided By

Metabolic Endocrine Education Foundation (MEEF)
PESI, Inc.
Metabolic Institute of America (MIA)

Back to top

Acknowledgement of Support

This CME activity is supported by an educational grant from AstraZeneca

Back to top

To get started:

Login / Register

CME information

View Agenda

Course presentations

To Receive a Certificate for This CME Activity

View the presentations in this CME activity and Complete the evaluation. Your certificate will be mailed to you Upon satisfactory completion of these documents.

Faculty Disclosures and Conflicts of Interest

It is the policy of PESI, Inc., Aspen CME Services and the Metabolic Endocrine Education Foundation, accreditors of this live educational activity that anyone that can affect the content of an educational activity must provide disclosure of financial relationships that they or their partner may have with commercial supporters.  Speakers are also required to disclose if their presentation will contain information on off-labeled, investigational, or unapproved use of a product.  The planning faculty,  speakers, and moderators for this activity have provided the following information:

Last First Relationship
Ghani Muhammed Nothing to disclose
DeFronzo Ralph

Advisory Board: BMS/Astrazeneca, Janssen
Speaker's Bureau: BMS/Astrazeneca, Janssen
Grant: BMS/Astrazeneca, Janssen

Ferrannini Ele Grant: Eli Lilly & Co, Boehringer Ingelheim
Advisory Board/Speaker's Bureau: MerckSharp&Dohm, Halozyme, GSK, BMS/AZ, Eli Lilly, Novartis, Daiichi, Sankyo, Sanofi
Staels Bart Nothing to Disclose
Handelsman Yehuda Research, Consultant, Lecturer: Amarin, Amgen, AZ, BMS, BI, BI-Lilly, diaDeux, DSI, Eisai, Gilead, Grifols, GSK, Hamni, Intarcia, Janssen, LipoScience, Lexicon, Merck, Novo Nordisk, Sanofi Takeda, Vivus
Asp Renee Nothing to disclose

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education, through the joint providership of PESI, Inc, and the Metabolic Endocrine Education Foundation (MEEF). PESI, Inc is accredited by the ACCME to provide continuing medication education for physicians.

AMA PRA Designation Statement
PESI, Inc designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to top

No part of this publication may be reproduced or transmitted in any other form or by any other means, electronic or mechanical, without first obtaining written permission © 2015 MEEF
For questions regarding this CME activity, please contact us

Back to top